|
XPO4 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62581059726108E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.99107397236276E-12 |
| Normal-vs-Stage2 |
1.94754999999214E-05 |
| Normal-vs-Stage3 |
2.23154827949656E-13 |
| Normal-vs-Stage4 |
2.02615701994091E-13 |
| Stage1-vs-Stage2 |
4.662200E-01 |
| Stage1-vs-Stage3 |
6.656100E-02 |
| Stage1-vs-Stage4 |
1.001010E-03 |
| Stage2-vs-Stage3 |
6.211600E-02 |
| Stage2-vs-Stage4 |
8.237400E-03 |
| Stage3-vs-Stage4 |
1.705230E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.77555756156289E-15 |
| Normal-vs-AfricanAmerican |
4.14240000000676E-05 |
| Normal-vs-Asian |
2.5337000275627E-09 |
| Caucasian-vs-AfricanAmerican |
5.691800E-01 |
| Caucasian-vs-Asian |
6.983200E-01 |
| AfricanAmerican-vs-Asian |
4.202000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.57172102794357E-14 |
| Normal-vs-Female |
1.7160717291631E-12 |
| Male-vs-Female |
1.150580E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.66450220063075E-11 |
| Normal-vs-Age(41-60Yrs) |
1.07980291375043E-12 |
| Normal-vs-Age(61-80Yrs) |
2.13618012168126E-12 |
| Normal-vs-Age(81-100Yrs) |
1.423350E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.016000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.149590E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.836970E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.084200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.370800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.159000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.634400E-02 |
| Classical-VS-Follicular |
8.283600E-01 |
| Classical-VS-Other |
1.421770E-01 |
| Classical-VS-Normal |
1.71629377376803E-12 |
| Tall-VS-Follicular |
6.750000E-02 |
| Tall-VS-Other |
4.876200E-01 |
| Tall-VS-Normal |
2.64440025432577E-10 |
| Follicular-VS-Other |
2.068800E-01 |
| Follicular-VS-Normal |
9.80269999617533E-08 |
| Other-VS-Normal |
2.443400E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.27435864480685E-13 |
| Normal-vs-N1 |
8.43950465068133E-11 |
| N0-vs-N1 |
1.762950E-01 |
|
|
